Growth Metrics

Myriad Genetics (MYGN) Income from Continuing Operations (2016 - 2025)

Historic Income from Continuing Operations for Myriad Genetics (MYGN) over the last 17 years, with Q3 2025 value amounting to -$27.4 million.

  • Myriad Genetics' Income from Continuing Operations fell 2398.19% to -$27.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$400.5 million, marking a year-over-year decrease of 24525.86%. This contributed to the annual value of -$127.3 million for FY2024, which is 5165.21% up from last year.
  • As of Q3 2025, Myriad Genetics' Income from Continuing Operations stood at -$27.4 million, which was down 2398.19% from -$330.5 million recorded in Q2 2025.
  • Over the past 5 years, Myriad Genetics' Income from Continuing Operations peaked at $24.6 million during Q3 2021, and registered a low of -$330.5 million during Q2 2025.
  • Over the past 5 years, Myriad Genetics' median Income from Continuing Operations value was -$31.2 million (recorded in 2023), while the average stood at -$46.7 million.
  • Its Income from Continuing Operations has fluctuated over the past 5 years, first surged by 26184.21% in 2021, then crashed by 80054.5% in 2025.
  • Over the past 5 years, Myriad Genetics' Income from Continuing Operations (Quarter) stood at -$7.6 million in 2021, then tumbled by 456.58% to -$42.3 million in 2022, then increased by 26.24% to -$31.2 million in 2023, then plummeted by 36.22% to -$42.5 million in 2024, then surged by 35.53% to -$27.4 million in 2025.
  • Its Income from Continuing Operations stands at -$27.4 million for Q3 2025, versus -$330.5 million for Q2 2025 and -$100000.0 for Q1 2025.